UCB's stock price seems, partly because of the recent share price rises, to be in line with most of the estimates. Most of the analysts say UCB is fairly priced now. Currently the company is being followed by 13 analysts. The average of the target prices for the stock equals 76,35 euros. This is around 0,18 percent more than the current price of 76,14 euros.
Over the current book year the total revenue will be 4,71 billion euros (consensus estimates). This is slightly more than 2017's revenue of 4,63 billion euros.
The analysts expect for 2018 a net profit of 862 million euros. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 4,63 euros. So the price/earnings-ratio equals 16,44.
Per share the analysts expect a dividend of 1,23 euros per share. The dividend yield is then 1,62 percent. The average dividend yield of the pharmaceutical companies equals a moderate 0,5 percent.
Based on the current number of shares UCB's market capitalization equals 14,33 billion euros. The UCB stock was the past 12 months quite volatile. Since last March the stock is 16 percent higher. This year the stock price moved between 60 and 81 euro. Since 2008 the stock price is almost 247 percent higher.
At 10.50 the stock trades 1,26 percent higher at 76,14 euros.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.